JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy

Michael T. Nedelcovych1,2, Ranjeet P. Dash1,2, Ying Wu1, Eun Yong Choi8, Rena S. Lapidus8, Pavel Majer9, Diane Abou11, Marie-France Penet4,7, Anastasia Nikolopoulou10, Alex Amor-Coarasa10, John Babich10, Daniel L. Thorek11, Rana Rais1,2, Clemens Kratochwil12, Barbara S. Slusher1,2,3,4,5,6*

1Johns Hopkins Drug Discovery, Departments of 2Neurology, 3Medicine, 4Oncology, 5Psychiatry, 6Neuroscience, 7Radiology and Radiological Science, Johns Hopkins School of Medicine, Baltimore, MD 21205, U.S.A.
8Translational Laboratory Shared Service, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD, 21201, U.S.A.
9Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic v.v.i., Prague, 166 10, Czech Republic
10Division of Radiopharmaceutical Sciences and MI(3), Department of Radiology, Weill Cornell Medicine, New York, NY, U.S.A.
11Department of Radiology, Washington University School of Medicine, Saint Louis, MO, 63110, U.S.A.
12Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany

Address Correspondence to:
*Barbara S. Slusher, PhD, Johns Hopkins Drug Discovery, 855 North Wolfe Street, Baltimore, Maryland, USA 21205, Phone: 410-614-0662, Fax: 410-614-0659, E-mail: bslusher@jhmi.edu

This manuscript has been withdrawn by the authors because data included in the original manuscript will be separated into two different manuscripts and submitted for publication to two different journals. The authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.